The Sumitomo Corporation, the international integrated trading company handling separation products from major global companies, is trying to win the Indian pharma machinery market with a unique chromatographic separation system.

The company, in the year 2006, introduced chromatographic separation system from Mitsubishi Chemical Corporation, with two fraction separating ISMB process and three fraction separating new MCI process in India. The product has made a significant market in the European Union countries and is expected to win the Indian market soon, according to Massimiliano Paciolla, Manager, Chemical Department (Milano), Sumitomo Corporation Italia S p A.

The company has introduced two brand products from Resindion SRL, the subsidiary of Mitsubishi Chemical Corporation. The Sepabeads FP EB series (Bioseperation media) and Sepabeads EC series (Enzyme carriers) are known for their unique characteristics in separation technology, by considering the difference between pharmaceutical products and bio pharmaceutical products, according to Paciolla.

The synthetic absorbents, including the Sepabeads brand are aqueous solutions having the lowest solvent content with pure or diluted solvent solutions in elution process. The pH change on absorption process and elution process are significant in the resultant products. The synthetic absorbents have advantages including traits on stability in a wide pH range and cost effectiveness with long operation life, simple regeneration method with chemicals at low ecological impact, according to the company officials.

The company is one of the major product/service providers of the global pharmaceutical industry with its core competency in risk management, IT Solutions, financial services, logistics solutions, business development, intellectual capital and global network and global relations, added company sources.

The company has established close relations with over 100,00 business partners and operates over 160 offices and over 720 subsidiaries across the world. They said that the company has its focus in markets in India, as the pharmaceutical and biotechnology industry and R&D works are mushrooming.